Compare The Coca-Cola Co K (KO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Recursion Pharmaceuticals Inc — how do they compare? The Coca-Cola Co K trades at $88.05 (market cap $377.63B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: The Coca-Cola Co K is far larger — about 176.5× Recursion Pharmaceuticals Inc's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KO | RXRX | |
|---|---|---|
Market Cap | $377.63B | $2.14B |
Volume | 14,894,568 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $6.79 |
52-Week Low | $66.37 | $2.84 |
Typical Hold Time | 154 Days | 23 Days |
Enterprise Value | $404.81B | $1.66B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.77, up 2.27% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 28.56% net margin, and 44.23% ROE. Recent institutional buying activity and positive analyst sentiment (60% buy ratings) support the stock's upward trajectory. KO maintains its dividend aristocrat status with 64 consecutive years of dividend increases, paying $0.53 per share in the upcoming H2-26 distribution.
KO presents a compelling investment case with stable revenue growth, exceptional profitability, and strong institutional support. The stock trades at a premium valuation (P/E 26.36) but justifies it with consistent execution. Key risks include regional demand divergence in Asia and elevated debt levels. With a consensus price target of $95.75 offering 9% upside potential, KO remains a quality defensive holding for dividend-focused investors seeking stable returns.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
